The Innovation Medicine,
Год журнала:
2024,
Номер
unknown, С. 100094 - 100094
Опубликована: Янв. 1, 2024
<p>Bladder
cancer
(BCa)
is
the
most
common
and
lethal
urological
malignancy.
Lymphatic
metastasis
main
type
of
a
poor
prognostic
factor
for
bladder
patients.
Although
several
treatments
are
approved
BCa
patients,
some
patients
still
resistant
to
current
therapy.
The
tumor
microenvironment
(TME),
which
consists
diverse
cellular
components,
crucial
mediator
progression
treatment
resistance.
However,
literature
on
interactions
between
TME
lacks
coherence
systematic
analysis,
while
impact
intratumoral
heterogeneity
(ITH)
tumorigenesis
has
not
been
fully
summarized.
Iterative
insights
into
factors
intrinsic
extrinsic
cells
that
regulate
response
critically
needed.
Here,
we
provide
an
overview
knowledge
multilevel
crosstalk
TME,
including
protein-coding
genes
epigenetic
in
cells,
tumor-associated
macrophages
(TAMs),
cancer-associated
fibroblasts
(CAFs),
neutrophils
(TANs),
endothelial
(ECs),
lymphatic
(LECs)
other
play
roles
tumorigenesis,
progression,
development
drug
We
also
summarize
advanced
therapeutic
approaches
targeting
discuss
challenges
future
perspectives
associated
with
therapies.</p>
International Journal of Molecular Sciences,
Год журнала:
2024,
Номер
25(7), С. 3779 - 3779
Опубликована: Март 28, 2024
Lung
adenocarcinoma
(LUAD)
is
a
highly
prevalent
and
lethal
form
of
lung
cancer,
comprising
approximately
half
all
cases.
It
often
diagnosed
at
advanced
stages
with
brain
metastasis
(BM),
resulting
in
high
mortality
rates.
Current
BM
management
involves
complex
interventions
conventional
therapies
that
offer
limited
survival
benefits
neurotoxic
side
effects.
The
tumor
microenvironment
(TME)
system
where
cancer
cells
interact
various
elements,
significantly
influencing
behavior.
Immunotherapies,
particularly
immune
checkpoint
inhibitors,
target
the
TME
for
treatment.
Despite
their
effectiveness,
it
crucial
to
understand
metastatic
specific
characteristics
TME,
including
cell–cell
communication
mechanisms,
refine
treatments.
Herein,
we
investigated
from
(LUAD-BM)
primary
tumors
across
(I,
II,
III,
IV)
using
single-cell
RNA
sequencing
(scRNA-seq)
publicly
available
datasets.
Our
analysis
included
exploring
non-immune
cell
composition
expression
profiles
functions
type-specific
genes,
investigating
interactions
between
different
within
TME.
results
showed
T
constitute
majority
present
tumors,
whereas
microglia
represent
most
dominant
type
BM.
Interestingly,
exhibit
significant
increase
COX
pathway.
Moreover,
have
shown
primarily
oligodendrocytes
endothelial
cells.
One
interaction
was
identified
DLL4
NOTCH4,
which
demonstrated
relevant
association
oligodendrocytes.
Finally,
observed
several
genes
HLA
are
suppressed
tissue.
study
reveals
molecular
cellular
dynamics
BM-LUAD,
providing
path
improved
patient
outcomes
personalized
treatments
immunotherapies.
Pharmaceutics,
Год журнала:
2024,
Номер
16(9), С. 1228 - 1228
Опубликована: Сен. 20, 2024
Chimeric
antigen
receptor
(CAR)
T
cell
therapy
has
emerged
as
a
groundbreaking
treatment
for
hematological
cancers,
yet
it
faces
significant
hurdles,
particularly
regarding
its
efficacy
in
solid
tumors
and
concerning
associated
adverse
effects.
This
review
provides
comprehensive
analysis
of
the
advancements
ongoing
challenges
CAR-T
therapy.
We
highlight
transformative
potential
nanotechnology
enhancing
by
improving
targeting
precision,
modulating
immune-suppressive
tumor
microenvironment,
overcoming
physical
barriers.
Nanotechnology
facilitates
efficient
CAR
gene
delivery
into
cells,
boosting
transfection
efficiency
potentially
reducing
costs.
Moreover,
offers
innovative
solutions
to
mitigate
cytokine
release
syndrome
(CRS)
immune
effector
cell-associated
neurotoxicity
(ICANS).
Cutting-edge
platforms
real-time
monitoring
activity
are
also
discussed.
By
integrating
these
advancements,
we
aim
provide
valuable
insights
pave
way
next
generation
therapies
overcome
current
limitations
enhance
therapeutic
outcomes.
The Innovation Medicine,
Год журнала:
2024,
Номер
unknown, С. 100094 - 100094
Опубликована: Янв. 1, 2024
<p>Bladder
cancer
(BCa)
is
the
most
common
and
lethal
urological
malignancy.
Lymphatic
metastasis
main
type
of
a
poor
prognostic
factor
for
bladder
patients.
Although
several
treatments
are
approved
BCa
patients,
some
patients
still
resistant
to
current
therapy.
The
tumor
microenvironment
(TME),
which
consists
diverse
cellular
components,
crucial
mediator
progression
treatment
resistance.
However,
literature
on
interactions
between
TME
lacks
coherence
systematic
analysis,
while
impact
intratumoral
heterogeneity
(ITH)
tumorigenesis
has
not
been
fully
summarized.
Iterative
insights
into
factors
intrinsic
extrinsic
cells
that
regulate
response
critically
needed.
Here,
we
provide
an
overview
knowledge
multilevel
crosstalk
TME,
including
protein-coding
genes
epigenetic
in
cells,
tumor-associated
macrophages
(TAMs),
cancer-associated
fibroblasts
(CAFs),
neutrophils
(TANs),
endothelial
(ECs),
lymphatic
(LECs)
other
play
roles
tumorigenesis,
progression,
development
drug
We
also
summarize
advanced
therapeutic
approaches
targeting
discuss
challenges
future
perspectives
associated
with
therapies.</p>
